EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Selinexor: Targeting a novel pathway in multiple myeloma

Clifton C Mo, Andrew J Yee iD, Shonali Midha iD, Monique A Hartley-Brown iD, Omar Nadeem, Elizabeth K O'Donnell, Giada Bianchi, Adam S Sperling iD, Jacob P Laubach, Paul G Richardson iD

eJHaem · 2023-08 · 4 (3) · 792-810

DOI: 10.1002/jha2.709 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift eJHaem, online erschienen am 15.05.2023. Verfasst von Clifton C Mo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachu…. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dana-Farber Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to the cytoplasm, including tumour suppressor proteins. Inhibition of this process has demonstrated substantial antimyeloma activity in preclinical studies, both alone and in combination with established MM therapeutics. Based on a clinical trial programme encompassing multiple combination regimens, selinexor‐based therapy has been approved for the treatment of relapsed/refractory MM (RRMM), with selinexor‐dexamethasone approved in the later‐relapse setting for penta‐refractory patients and selinexor‐bortezomib‐dexamethasone approved for patients who have received ≥1 prior therapy. Here, we provide a comprehensive review of the clinical data on selinexor‐based regimens, including recent updates from the 2022 American Society of Hematology annual meeting, and summarise ongoing studies of this novel targeted agent in newly diagnosed MM and RRMM.

Schlagwörter

Stichwörter der Autor:innen

XPO1multiple myelomanuclear exportrefractoryrelapsedselective inhibitor of nuclear exporttargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.
  • Massachusetts General Cancer Center Harvard Medical School Boston Massachusetts USA.
  • Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA.

ORCID-Profile: Andrew J Yee, Shonali Midha, Monique A Hartley-Brown, Adam S Sperling, Paul G Richardson

Förderung

  • Dana-Farber Cancer Institute

Zitieren

APA

Mo, C. C., Yee, A. J., Midha, S., Hartley-Brown, M. A., Nadeem, O., O'Donnell, E. K., Bianchi, G., Sperling, A. S., Laubach, J. P., & Richardson, P. G. (2023). Selinexor: Targeting a novel pathway in multiple myeloma. eJHaem, 4(3), 792-810. https://doi.org/10.1002/jha2.709

Vancouver

Mo CC, Yee AJ, Midha S, Hartley-Brown MA, Nadeem O, O'Donnell EK, et al. Selinexor: Targeting a novel pathway in multiple myeloma. eJHaem. 2023;4(3):792-810. doi:10.1002/jha2.709

BibTeX
@article{Mo2023,
  author = {Mo, Clifton C and Yee, Andrew J and Midha, Shonali and Hartley-Brown, Monique A and Nadeem, Omar and O'Donnell, Elizabeth K and Bianchi, Giada and Sperling, Adam S and Laubach, Jacob P and Richardson, Paul G},
  title = {Selinexor: Targeting a novel pathway in multiple myeloma},
  journal = {eJHaem},
  year = {2023},
  volume = {4},
  number = {3},
  pages = {792--810},
  doi = {10.1002/jha2.709}
}
Kostenlos starten →